INCY - インサイト （Incyte Corporation）

Incyte (INCY) announced Friday that a group of experts in the EU recommended the approval of ruxolitinib cream for non-segmental vitiligo with facial involvement. Read the full story here.

At approval, ruxolitinib cream will be the first treatment for repigmentation in non-segmental vitiligo available in the European Union (EU) In Europe, there are approximately 1.5 million patients…

https://www.investing.com/news/assorted/incyte-announces-positive-chmp-opinion-for-ruxolitinib-cream-for-treatment-of-nonsegmental-vitiligo-in-adults-and-adolescents-432SI-3013712

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents

Incyte Corp. (INCY), Yum China Holdings (YUMC) and Centene Corp. (CNC) are three bearish-looking stocks you should consider shorting this week, technical analyst Bob Lang writes in his latest edition of Bearish Bets.

Eli Lilly and Company found using ticker (LLY) have now 23 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 440 and 268 calculating the mean target price we have 389.3. Given that the stocks previous close was at 364.99 this now indicates there is a potential upside of 6.7%. There is a 50 day moving average of 362.32 while the 200 day moving average is 322.72. The market cap for the company is $345,010m. Company Website: https://www.lilly.com [stock_market_widget type="chart" template="basic" color="green" assets="LLY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $367,989m based on the market concensus. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Incyte Corporation (NASDAQ:INCY) has a beta value of 0.71 and has seen 0.7 million shares traded in the last trading session. The company, currently valued at $17.68B, closed the last trade at $80.32 per share which meant it gained $0.84 on the day or 1.06% during that session. The INCY stock price is -5.65% off … Analysts Are Recommending Incyte Corporation (INCY) As A Buy Candidate Read More »

Eli Lilly and Company with ticker code (LLY) now have 23 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 440 and 268 with a mean TP of 386.47. Given that the stocks previous close was at 359.64 this is indicating there is a potential upside of 7.5%. The 50 day moving average now sits at 356.93 and the 200 day MA is 319.05. The market cap for the company is $349,371m. Find out more information at: https://www.lilly.com [stock_market_widget type="chart" template="basic" color="green" assets="LLY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $375,435m based on the market concensus. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing breast cancer mortality rate. As it stands now, breast cancer is the second most common cause of cancer death in women in the U.S. It is estimated that 43,780 people — 43,250 women and 530 men — will die from breast cancer this year alone. Globally, female breast cancer is the fifth leading cause of death. An estimated 684,996 women worldwide died from breast cancer in 2020, with metastatic breast cancer causing the vast majority of the deaths. The increasing death rate has led companies like BriaCell Therapeutics Corp. (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT) to advance research and development into therapies that could prove more effective against breast and other cancers. Focusing initially on breast cancer, BriaCell is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight the disease.

Incyte (Nasdaq:INCY) today announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel anti-mutant calreticulin (CALR)-targeted monoclonal antibody. Pre-clinical data indicate that INCA033989 can alter disease course by reducing mutant CALR allele burden and thus may be an efficacious and safe treatment in patients with myelofibrosis

Incyte Corporation (NASDAQ:INCY) has a beta value of 0.71 and has seen 0.7 million shares traded in the last trading session. The company, currently valued at $17.68B, closed the last trade at $80.32 per share which meant it gained $0.84 on the day or 1.06% during that session. The INCY stock price is -5.65% off … Analysts Are Recommending Incyte Corporation (INCY) As A Buy Candidate Read More »

Eli Lilly and Company with ticker code (LLY) now have 23 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 440 and 268 with a mean TP of 386.47. Given that the stocks previous close was at 359.64 this is indicating there is a potential upside of 7.5%. The 50 day moving average now sits at 356.93 and the 200 day MA is 319.05. The market cap for the company is $349,371m. Find out more information at: https://www.lilly.com [stock_market_widget type="chart" template="basic" color="green" assets="LLY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $375,435m based on the market concensus. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing breast cancer mortality rate. As it stands now, breast cancer is the second most common cause of cancer death in women in the U.S. It is estimated that 43,780 people — 43,250 women and 530 men — will die from breast cancer this year alone. Globally, female breast cancer is the fifth leading cause of death. An estimated 684,996 women worldwide died from breast cancer in 2020, with metastatic breast cancer causing the vast majority of the deaths. The increasing death rate has led companies like BriaCell Therapeutics Corp. (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT) to advance research and development into therapies that could prove more effective against breast and other cancers. Focusing initially on breast cancer, BriaCell is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight the disease.

Incyte (Nasdaq:INCY) today announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel anti-mutant calreticulin (CALR)-targeted monoclonal antibody. Pre-clinical data indicate that INCA033989 can alter disease course by reducing mutant CALR allele burden and thus may be an efficacious and safe treatment in patients with myelofibrosis

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aclaris, Astellas, Biocon, CMS Aesthetics, Cosmo, ERS Genomics, Focus-X, Full-Life Technologies, Immutep, Incyte, Legochem, Merck KGaA, Pediatrix, Pfizer, Sirona, Sotio, Viatris, Wanbang.